Fiasp Penfill is an insulin aspart solution for injection used to treat diabetes [1]. It is delivered via a Penfill cartridge, which is inserted into a Novo Nordisk insulin pen [1]. Fiasp is a fast-acting mealtime insulin, designed to be taken before or shortly after meals [1].
When does Fiasp patent expire?
The patent expiry for Fiasp is complex and involves multiple patents related to the formulation, manufacturing, and delivery devices. DrugPatentWatch.com tracks these patents, providing specific expiry dates for different intellectual property protections [2]. Generally, patents for such drugs can expire at different times, affecting different aspects of the product's lifecycle, including the potential for generic or biosimilar competition.
What is Fiasp and how does it work?
Fiasp is a rapid-acting analog of human insulin. It is formulated with niacinamide and L-arginine, which helps it absorb faster into the bloodstream compared to other rapid-acting insulins [1]. This faster absorption allows for better post-meal glucose control when taken at mealtimes [1]. Fiasp is delivered using a pre-filled insulin pen and a cartridge system [1].
Who manufactures Fiasp?
Fiasp is manufactured by Novo Nordisk, a global healthcare company specializing in diabetes care [1].
What are the alternatives to Fiasp?
Other rapid-acting insulins are available for mealtime glucose control. These include insulin lispro (e.g., Humalog), insulin aspart (e.g., Novolog), and insulin glulisine (e.g., Apidra) [3]. The choice of insulin depends on individual patient needs, glycemic control, and physician recommendation [3].
How does Fiasp compare to other rapid-acting insulins?
Fiasp's primary differentiator is its faster onset of action due to its formulation with niacinamide and L-arginine [1]. Clinical studies have shown that Fiasp can lead to lower postprandial glucose levels compared to other rapid-acting insulins [1]. However, individual responses can vary, and factors like injection site, meal composition, and exercise also influence glucose control [1].
What are the side effects of Fiasp?
Common side effects of Fiasp include hypoglycemia (low blood sugar), allergic reactions, lipodystrophy (changes in fat tissue at injection sites), and injection site reactions such as redness, swelling, or itching [1]. Serious side effects can include generalized allergic reactions, including anaphylaxis [1].
Can Fiasp be used with an insulin pump?
Fiasp is indicated for use with a continuous subcutaneous insulin infusion (CSII) pump [1]. However, it is not recommended for use in CSII pumps without prior consultation with a healthcare provider and careful monitoring, as issues like line occlusions could lead to rapid hyperglycemia and ketoacidosis [1].
What is the dosage for Fiasp?
The dosage of Fiasp is individualized based on a patient's needs, blood glucose levels, and meal schedule. It is typically administered before or up to 20 minutes after the start of a meal [1]. Patients should follow their healthcare provider's instructions regarding dosage and timing [1].
What is the difference between Fiasp and Novolog?
Both Fiasp and Novolog are rapid-acting insulins containing insulin aspart. The key difference lies in their formulation. Fiasp includes niacinamide and L-arginine, which contribute to a faster absorption rate and an earlier onset of action compared to Novolog [1]. This can result in more effective control of post-meal blood sugar spikes [1].
Sources:
[1] https://www.fiasp.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/diabetes/in-depth/diabetes-treatment/art-20046984